RxDoctor Payments Data

Sameen Ahmad, MD

Psychiatry · Palos Heights, ILNPI 1720243025

Payments from drug & device makers

$3,602in general payments, 2019–2025

Across 119 payments — averaging $30.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Brainsway USA Inc$2K
  • AbbVie$1K
  • Sunovion Pharmaceuticals Inc.$274
  • Takeda Pharmaceuticals U.S.A., Inc.$73
  • Otsuka America Pharmaceutical, Inc.$62
  • Lundbeck LLC$52
  • plus $126 from 3 others

What the payments were for

  • Food & beverage$3,55599%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,602 in reported general payments places this provider in the 85th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$81,097
Medicare patients
96
Services billed
850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate26$66,843
VraylarCariprazine Hcl28$46,675
NuedextaDextromethorphan Hbr/Quinidine13$18,354
Lurasidone Hcl31$9,326
VyvanseLisdexamfetamine Dimesylate15$5,938
Paliperidone ErPaliperidone19$2,993
Aripiprazole66$2,597
Quetiapine Fumarate104$2,495
Ziprasidone Hcl25$1,905
Duloxetine Hcl119$1,730
Bupropion XlBupropion Hcl49$1,559
Lamotrigine117$1,450
Fluoxetine Hcl79$1,263
Clozapine47$1,254
Olanzapine56$1,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$47$66,84326 claims
AbbVieVraylar$1,140$46,67528 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$73$5,93815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Palos Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →